The effect of semaglutide on liver function in NAFLD patietns with DM
Not Applicable
Not yet recruiting
- Conditions
- AFLD
- Registration Number
- JPRN-UMIN000046309
- Lead Sponsor
- Kyoto Prefectural University of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Liver cirrhosis Patients deemed inappropriate by the physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in ALT, MRI-PDFF, MR elastography between 24 weeks oral semaglutide therapy
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie semaglutide's impact on liver function in AFLD patients with diabetes mellitus?
How does semaglutide compare to GLP-1 receptor agonists in improving liver function for AFLD patients with DM?
Which biomarkers correlate with semaglutide response in AFLD patients with diabetes mellitus?
What adverse events are associated with semaglutide in AFLD patients with diabetes mellitus?
Are there combination therapies involving semaglutide for AFLD with diabetes mellitus showing enhanced efficacy?